Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Core Laboratories (CLB) EBITDA (2022 - 2026)

Core Laboratories filings provide 5 years of EBITDA readings, the most recent being $5.4 million for Q1 2026.

  • On a quarterly basis, EBITDA fell 32.05% to $5.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $21.4 million, a 68.92% decrease, with the full-year FY2025 number at $23.9 million, down 67.22% from a year prior.
  • EBITDA hit $5.4 million in Q1 2026 for Core Laboratories, up from -$27.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $24.5 million in Q3 2025 to a low of -$28.2 million in Q4 2023.
  • Median EBITDA over the past 5 years was $18.1 million (2023), compared with a mean of $11.2 million.
  • Biggest five-year swings in EBITDA: soared 162.87% in 2024 and later crashed 254.63% in 2025.
  • Core Laboratories' EBITDA stood at $19.5 million in 2022, then plummeted by 244.32% to -$28.2 million in 2023, then surged by 162.87% to $17.7 million in 2024, then crashed by 254.63% to -$27.4 million in 2025, then surged by 119.87% to $5.4 million in 2026.
  • The last three reported values for EBITDA were $5.4 million (Q1 2026), -$27.4 million (Q4 2025), and $24.5 million (Q3 2025) per Business Quant data.